A third of the clinical trial results that federal regulators reviewed to approve drugs made by large pharmaceutical companies in 2012 were never publicly reported, according to a new study that grades companies on their transparency.
To assemble the report, a handful of dogged researchers pored over thousands of pages of regulatory documents, counting up the number of trials Food and Drug Administration regulators reviewed, versus how many trials were published or publicly reported. The result is an inaugural transparency report card -- essentially an index showing just how much of the evidence about how the 15 drugs actually work in people is publicly available.
Read Full Article »